- Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
- Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
More ▼
Key statistics
As of last trade Silo Pharma Inc (SILO:NAQ) traded at 2.27, -25.48% below its 52-week high of 3.05, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.09 |
---|---|
High | 2.33 |
Low | 1.96 |
Bid | 2.26 |
Offer | 2.33 |
Previous close | 2.03 |
Average volume | 22.96k |
---|---|
Shares outstanding | 2.80m |
Free float | 2.62m |
P/E (TTM) | -- |
Market cap | 5.69m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of May 21 2024 18:50 BST.
More ▼